JP2008179620A - Muscular atrophy inhibitor - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a muscular atrophy inhibitor which has more effective and safe muscular atrophy inhibition and can be used for a long period of time. <P>SOLUTION: The muscular atrophy inhibitor contains Panax ginseng as an active ingredient. Preferably, the muscular atrophy inhibitor further contains at least one of creatine and a casein decomposed peptide. As the Panax ginseng, Panax noto-ginseng is preferred, and an extract thereof with water and its product washed with ethanol are more preferred. Further, as the casein decomposed protein, a 12C peptide is preferred. <P>COPYRIGHT: (C)2008,JPO&INPIT

Description

  The present invention relates to a muscle atrophy inhibitor that effectively suppresses muscle atrophy.

  When a long-term bed rest or rest is forced due to an injury or morbidity such as a fracture, muscle atrophy occurs, and it takes time to return to daily life, and in some cases, there is a risk of disturbing daily life. Even when healthy, due to lack of daily exercise and aging, muscle atrophy may occur, as well as trouble with daily life. Furthermore, in a special case, it is known that people who are placed in a weightless environment such as space flight also cause muscle atrophy and take time to adapt to daily life.

  When muscle atrophy occurs, exercise becomes difficult and so-called quality of life decreases. When exercise becomes difficult, the sick can make the condition worse, and the elderly can shorten their lives. When muscle atrophy occurs, it is important to recover a certain amount of exercise continuously while taking proper nutrition. In order to recover muscles by such exercise therapy, the intake of nutrients and the amount of exercise are appropriately set, and the person needs the perseverance to continue. Therefore, healthy people who have been temporarily inadequate due to injury, etc. can recover muscles by exercise therapy as long as they have patience. I have to say that it is difficult.

  Therefore, the development of drugs and supplements to prevent the sick and elderly, as well as healthy people who have suffered from lack of exercise for some reason, from causing muscle atrophy that causes a decline in the quality of life has been studied. Conventionally, several proposals have been made.

  For example, Patent Literature 1 proposes a muscle atrophy-suppressing composition containing fruit polyphenol as an active ingredient.

  Further, Patent Document 2 proposes a creatine oral replacement therapy agent containing creatine as an active ingredient for the purpose of treating or preventing a muscle nonuse syndrome.

JP 2001-089387 A Japanese translation of PCT publication No. 2002-530330

  The composition for inhibiting muscle atrophy disclosed in Patent Document 1 was developed based on information suggesting that oxidative stress is involved in disuse muscle atrophy induced by lack of exercise and the like, and has an antioxidant effect. It is a muscular atrophy inhibitor that attempts to suppress muscular atrophy by reducing the oxidative stress presumed to be the cause by using a fruit polyphenol having an active ingredient. However, although the cause of muscle atrophy is considered to be almost apparently due to lack of exercise clinically, it has not yet been clarified physiologically or pathologically. As described in Patent Document 1, oxidative stress may induce muscle atrophy, or may be based on other causes. Ingestion of such specific polyphenols can suppress all muscle atrophy. It is not possible, and there are limits to effectiveness.

  The creatine oral replacement therapy agent disclosed in Patent Document 2 is a medical agent for treating or preventing a muscle nonuse syndrome including muscle atrophy by supplementing creatine as a material important for muscle energy production. This medical drug was developed based on the suggestion that the decline in exercise capacity associated with aging is due to a decrease in the body's creatine level. To promote muscle regeneration and maintenance. However, because the cause of muscle atrophy has not yet been fully elucidated, there may be other approaches other than creatine supplementation.

  This invention is made | formed in view of the said conventional problem, Comprising: The subject is that a muscle atrophy inhibitory action is more effective and safe, and provides the muscle atrophy inhibitor which can be used for a long term. is there.

  In order to solve the above-mentioned problems, the inventors of the present application have made extensive studies, experiments, and studies. As a result, they have obtained the following knowledge.

That is, ingredients that are safe for long-term ingestion and have a high muscle atrophy inhibitory effect have been screened for a group of plant extracts.
As a result, it was confirmed that the ginsengs such as the ginseng and the ginseng have a high inhibitory effect on muscle atrophy.

  Moreover, it is although it does not specifically limit as a usage form of the ginseng ginseng, It is preferable to use as an extract. And as an extract, what is based on water extraction is good, and when including the process of washing and refining the crude extract with water using an organic solvent, it is clear that it has the highest muscle atrophy suppression effect. became.

  In the present invention, the effect of inhibiting muscle atrophy includes a decrease in muscle mass, a decrease in maximum muscle strength, a decrease in maximum ability, an increase in muscle relaxation time, premature muscle fatigue, a decrease in glucose uptake, an increase in lipid content, and muscle energy. It is an action that reduces or prevents the symptoms of decline that occur in muscles such as a decrease in holding power, a decrease in muscle blood flow, and a movement control disorder.

  As is well known, the ginseng ginseng has various actions in various documents, and application examples based on the actions are disclosed. However, none of the disclosures mentions or suggests that the ginseng ginseng has the effect of suppressing the aforementioned muscle atrophy. For example, Japanese Patent Application Laid-Open No. 2004-189619 discloses a composition containing one or more selected from the group consisting of ginseng, sancinin ginseng, american ginseng and tochiban ginseng and vitamin B. The effects of carrots disclosed here are nourishing and tonic effects, and the inhibitory effect on muscle atrophy is not described or suggested at all.

  As described above, the present inventors conducted repeated screening on many plants and extracts thereof as to whether or not they have a muscle atrophy inhibitory effect and, if so, what effect can be expected. In addition, the present inventors have found out that the ginseng ginseng has a particularly remarkable muscular atrophy inhibitory effect. As a result of further investigation on the action mechanism of muscular atrophy by this ginseng, as shown in the examples described later, the proliferation and differentiation action of myoblasts brings about the result of promoting the enhancement of muscle cells. It has been found that there is a possibility that a muscle atrophy-suppressing action may be brought about based on both actions.

  Furthermore, when many compounds were screened for the presence or absence of a compound that promotes the muscle atrophy-suppressing effect of the ginseng ginseng, by adding at least one of creatine and casein degrading peptide to the extract of ginseng ginseng, It was confirmed that the muscular atrophy inhibitory effect possessed by the ginseng is enhanced.

The present invention has been made based on such knowledge. That is, the muscular atrophy inhibitor according to the present invention is characterized by containing ginseng ginseng as an active ingredient.
In the muscle atrophy inhibitor of the present invention, the content of the ginseng which is an active ingredient is preferably a water extract. This water extract is preferably one obtained by purifying a crude extract using water by further washing with an organic solvent. In this case, it is preferable to use 80 to 100% ethanol as the organic solvent.
The muscle atrophy inhibitor according to the present invention preferably further contains at least one of creatine and casein degrading peptide.

  The muscle atrophy inhibitor according to the present invention has both an action of proliferating and differentiation of myoblasts, and contains aspergillus ginseng that exhibits an excellent effect of suppressing muscle atrophy based on such action as an active ingredient. Yes. Therefore, by appropriately taking the muscle atrophy inhibitor according to the present invention, it effectively suppresses muscle atrophy that occurs in the case of lack of exercise for a long time due to morbidity or injury, and the quality of life is improved by muscle atrophy. It becomes possible to reduce or prevent damage.

  As described above, the muscular atrophy inhibitor according to the present invention is characterized by containing ginseng ginseng as an active ingredient. Furthermore, it preferably contains at least one of creatine and casein degrading peptide.

  In the present invention, the effect of suppressing muscle atrophy includes a decrease in muscle mass, a decrease in maximum muscle strength, a decrease in maximum ability, an increase in muscle relaxation time, premature muscle fatigue, a decrease in muscle energy retention, and a decrease in muscle blood flow. It is an action to reduce or prevent the decline symptoms that occur in muscles such as impaired motor control. This muscular atrophy action is effectively brought about by the ginseng which is an active ingredient. It is considered that this effect of inhibiting ginseng muscle atrophy is obtained by having both the action of promoting the proliferation of myoblasts and the function of promoting the differentiation of myoblasts.

  The action of promoting the proliferation of myoblasts means that the cell proliferation in the case where a sample aqueous solution is added to cultured myoblasts is superior to that without addition. The degree of proliferation of this myoblast can be evaluated by measuring how much proliferation has been promoted compared to the case of no addition.

  On the other hand, the action of promoting the differentiation of the myoblasts means that the cell proliferation in the case where the sample aqueous solution is added to the cultured myoblasts is differentiated as compared with the case of no addition. The degree of differentiation of this myoblast can be evaluated by measuring the creatine kinase activity of the cell.

  Next, the ginseng which is an active ingredient of the muscle atrophy inhibitor of the present invention, and creatine and casein degrading peptides which are optional active ingredients will be described individually.

  The ginseng ginseng used as an essential active ingredient of the muscular atrophy inhibitor of the present invention is a well-known medicinal plant classified as a herbaceous plant of the family Uridaceae. Examples of this ginseng include ginseng (also called ginseng and ginseng) and seven ginseng.

  Since this root ginseng contains a lot of active ingredients in its roots and rhizomes, the roots and rhizomes are kept in their original form or crushed, or further extracted by solvent extraction and concentrated. It is desirable to use it in the state of the extract which was dried and made into the powder.

  As a specific ginseng extract to be used, a water extract is preferable, and the process is not particularly limited, but 10 to 30 times the amount of water with respect to 1 weight of ginseng (dry matter). It is preferable to extract the active ingredient by stirring for 2 hours or more while keeping the temperature at 4 to 25 ° C., preferably 10 to 20 ° C. Usually, extraction is performed by dipping and stirring, and the resulting extract is formulated by applying appropriate treatments such as filtration, concentration, and lyophilization.

  Furthermore, the muscular atrophy inhibitory effect can be improved by including a step of separating the extraction residue from the ginseng extract. The step of residual separation is not particularly limited, but is performed by a known method such as filtration, centrifugation, or organic solvent washing. Preferably, a residue separation step using ethanol is used, and 1 to 3 times the amount of absolute ethanol is added to 1 weight of the ginseng water extract to obtain the active ingredient from the residue. Furthermore, it is preferable for the purification of the active ingredient to repeat the cleaning and purification step of the residual active ingredient using ethanol, but it is preferable for purification of the active ingredient. It is uneconomical due to the decline. The obtained extract is usually formulated by appropriate treatment such as stirring, centrifugation, filtration, and drying.

  In the case of using ginseng powder as the ginseng ginseng, the recommended intake for obtaining a muscle atrophy effect is preferably 0.1 mg / day to 100 g / day, more preferably 0.1 g / day to 50 g / day. Day. When the water extract of the ginseng is used, the recommended intake for obtaining a muscle atrophy effect is preferably 0.1 mg / day to 100 g / day, more preferably 50 mg / day to 25 g / day. . When an anhydrous ethanol washing process is included in the water extract of ginseng, the recommended intake for obtaining a muscle atrophy effect is preferably from 0.1 mg / day to 100 g / day, more preferably from 10 mg / day. 10 g / day. In such a range, the optimum intake amount, intake method, number of intakes, and intake period may be appropriately determined depending on the age, sex, and health status of the user. Even if the intake amount is increased from 100 g / day, the enhancement of the effect becomes a plateau state, which is uneconomical. If it is less than 0.1 mg / day, the effect of suppressing muscle atrophy cannot be expected.

  Creatine used as an optional active ingredient of the present invention is a kind of amino acid present in the living body, and can be obtained by extraction from meat, seafood, mammalian milk, or industrial production. Numerous studies have been conducted on preparation methods. For example, a method for separating and purifying creatine using an electrodialyzer, an ion exchange resin, a nanomembrane filter, and the like using a permeate obtained in the process of ultrafiltration of milk or dairy products as a raw material has been reported. In addition, the industrial production method is carried out by reacting sarcosine or sodium sarcosinate or potassium sarcosinate with cyanamide or O-methylisourea, and Ullmann's Encyclopedia of Industrial Chemistry, 5th edition, Volume A12, 552. Page, VCH-Verlagsgesellschaft, Weinheim (1987) and the publications cited therein.

  When this creatine is added to the muscular atrophy suppression of the present invention and used in combination with the arginaceae ginseng extract, which is the essential active ingredient, the intake is preferably 5 g / day to 0.05 mg / day. Even if the amount is increased from 5 g, the increase in the effect is slight, which is uneconomical. If it is less than 0.05 mg, the desired effect cannot be obtained.

  The casein-degrading peptide used as an optional active ingredient of the present invention is obtained from trypsin or pepsin hydrolyzate of casein, and Phe-Phe-Val-Ala-Pro-Phe-Pro-Glu-Val-Phe-Gly It contains a peptide represented by -Lys (Sequence Listing) or an acid addition salt thereof.

  As the casein, casein widely used as a food additive, for example, casein derived from milk, acid casein, and casein salts can be used. Commercially available trypsin and pepsin can be used, and these can be obtained by known hydrolysis methods described in JP-B-60-23085 and JP-B-61-51562.

  Specific examples of such casein degrading peptides include C12 peptides (manufactured by DMV) used in Examples described later. C12 peptide here is a peptide consisting of 12 amino acids obtained by enzymatic degradation of casein of milk protein.

  When this casein-degrading peptide is added to the suppression of muscular atrophy of the present invention and used in combination with the ginseng extract, which is the essential active ingredient, the intake is preferably 0.05 mg / day to 5 g / day. Even if the amount is increased from 5 g, the increase in the effect is slight, which is uneconomical. If it is less than 0.05 mg, the desired effect cannot be obtained.

  The muscle atrophy inhibitor of the present invention contains ginseng ginseng as an essential active ingredient, and preferably, at least one selected from creatine and casein-degrading peptide is added and used as an optional active ingredient. In the case where ginseng is used as an extract, the ratio is expressed as A: B = 1: 9 to 5: 5 when at least one kind selected from component A, creatine and casein degrading peptide is represented as component B. Yes, if set in this range, the combined effect is high. The most appropriate blending ratio for the user may be determined as appropriate according to age, sex, health condition, and the like.

  The preparation of the muscle atrophy inhibitor of the present invention can be performed by a known preparation technique, and appropriate additives can be added to the preparation. The muscle atrophy inhibitor of the present invention is desirably administered orally or transdermally.

  Examples of the muscle atrophy inhibitor according to the present invention will be described below. In addition, the Example shown below is a suitable illustration for demonstrating this invention, and does not limit this invention at all.

(Example 1)
Matsugura Pharmaceutical Co., Ltd. 100 g rice powder was diffused in 2000 g water and stirred for 3 hours while maintaining at 15 ° C. The supernatant obtained by centrifugation at 3000 rpm for 10 minutes was filtered and concentrated to about 15 times to obtain a seven-ninjin ginseng extract.

Furthermore, 95% ethanol (manufactured by Wako Pure Chemical Industries, Ltd.) was added to the above-mentioned rice field ginseng extract three times in volume, stirred at room temperature for 2 hours, and then centrifuged at 3000 rpm for 10 minutes to obtain a precipitate. (Crude extract with water) was obtained. The precipitate was washed twice with absolute ethanol (manufactured by Wako Pure Chemical Industries, Ltd.), suction filtered, dried at room temperature, and then washed with ethanol to obtain “Tanachi ginseng water extract ethanol washed product”.
The obtained rice ginseng water extract ethanol-cleaned product (water extract-cleaned purified product) was about 25% by weight with respect to 100% by weight of Matsuchi Pharmaceutical Co., Ltd.

  In the following Example 2, the test method and the results performed on muscle cultured cells and muscle atrophy model animals using the “Tanachi ginseng water extract ethanol-washed product” obtained in the above Example will be described. .

(Example 2)
In Example 2, for the ginseng ginseng (samples 1 and 2 below), which is an essential active ingredient constituting the muscle atrophy inhibitor according to the present invention, and IGF-1 (sample 3 below for comparison), The myoblast proliferation promoting effect was evaluated as follows. In addition, IGF-1 used for comparison is insulin-like growth factor-1 and is a pharmaceutical product exhibiting a myoblast proliferation action.

  As a target myoblast, a mouse-derived myoblast (trade name “C2C12”) manufactured by Dainippon Sumitomo Pharma Co., Ltd. was used. In addition, “Tanachi ginseng extract powder” manufactured by Matsuura Pharmaceutical Co., Ltd. as essential active ingredient sample 1, and “Tanachi ginseng water extract ethanol-washed product” obtained in Example 1 above as sample 2 are comparative samples. The above-mentioned IGF-1 was prepared as 3. The medium used was DMEM (Dulbecco's Modified Eagle's Medium) manufactured by Invitrogen.

5 × 10 ⁴ myoblasts were suspended in 400 μL of medium (DMEM containing 10% FBS, 100 units / mL penicillin, 100 μg / mL streptomycin), seeded in a 25-well plate, It was fixed by culturing for 3 hours under% CO ₂ .

  Thereafter, the medium was changed to 400 μL for evaluation medium [DMEM containing 0.5% FBS (fetal bovine serum), 100 units / mL penicillin, 100 μg / mL streptomycin, samples 1 to 3]. The evaluation concentrations of Samples 1 to 3 were 0.1, 1, 10, and 100 ppm as final concentrations. A 1% aqueous solution (hydrophobic sample was an ethanol solution) was prepared for each of Samples 1 to 3, and appropriately added so as to have a final concentration.

After culturing the aforementioned medium for 2 days, the medium was removed, 200 μL of DMEM supplemented with 10% Alamar Blue, 0.5% FBS, 100 units / mL penicillin, 100 μg / mL streptomycin was added, and after 3 hours of incubation, fluorescence was added. The fluorescence value (Ex544, Em590) was measured with a plate reader (fluorescence intensity was proportional to the number of cells).
The relative degree of proliferation was calculated by the following formula (1).
(Relative growth rate) = (Fluorescence intensity when sample is added) ÷ (Fluorescence intensity when sample is not added)
... (1)

  The fluorescence intensity due to the addition of each sample was measured with respect to the fluorescence intensity of 1.00 without addition of the sample. While the fluorescence intensity of sample 3 (IGF-1) added was 1.48, the fluorescence intensity of sample 1 (Tanachi ginseng extract powder) added was 1.36, and sample 2 ( Fluorescence intensity of the one added with the ginseng water extract (ethanol washed product) is 1.40, and the myoblast proliferation action of the ginseng (samples 1 and 2) is IGF-1 (a highly effective pharmaceutical). It was confirmed that the sample 3) was almost the same as the case of addition.

(Example 3)
In Example 3, the effect of promoting differentiation of myoblasts was evaluated as follows for the ginseng which is an essential active ingredient constituting the muscle atrophy inhibitor according to the present invention.

  As a target myoblast, a mouse-derived myoblast (trade name “C2C12”) manufactured by Dainippon Sumitomo Pharma Co., Ltd. was used. In addition to Sample 1 and Sample 2, as a sample for evaluation, creatine (“Creatine Citrate (trade name)” manufactured by Degussa Bioactives) was prepared as Comparative Sample 4. The medium used was DMEM (Dulbecco's Modified Eagle's Medium) manufactured by Invitrogen.

  The myoblasts (C2C12) were seeded on a 12-well cell culture plate, and cultured to 90% confluence in 1 mL of culture medium DMEM + 10% FBS + 1% penicillin-streptomycin. The myoblasts were washed twice with 1 mL of DMEM + 1% penicillin-streptomycin, and then 1 mL of DMEM + 1% penicillin-streptomycin was subjected to 100 ppm, 1000 ppm, and 10000 ppm evaluation samples 1 and 2 shown below (Table 2). 10 μL of sample 4 was added to obtain a culture solution for evaluation with final concentrations of 1 ppm, 10 ppm, and 100 ppm.

  The culture medium for evaluation was replaced with the same culture medium after 3 days, and cultured for 5 days to induce differentiation. Each sample was dissolved in distilled water or ethanol at a concentration of 1%, sterilized by filter, diluted with DMEM + 1% penicillin-streptomycin 1-fold, 10-fold, and 100-fold to give 10000 ppm, 1000 ppm, and 100 ppm solutions, respectively.

  In order to quantify the degree of differentiation of myoblasts, creatine kinase activity used as a differentiation marker in the literature (Z-Q cheng, Jornal of Endcrinology, 167, 175-182 (2000)) was measured. For creatine kinase activity, cells were lysed with 100 μL of Cellitic M (Sigma) supplemented with 1% protease inhibitor cocktail (Sigma), and the supernatant was diluted 100-fold with PBS (phosphate buffered saline). The sample was measured according to the method of CPKII Test Wako (manufactured by Wako Pure Chemical Industries, Ltd.). As an index indicating the effect of each sample for evaluation, differentiation promotion rate (= creatine kinase activity when component sample was added / creatine kinase activity when no component was added) was used.

  The measured differentiation promotion rate was 1.10 times for the sample 1 of the ginseng extract powder, 1.36 times for the sample 2 of the ethanol extract of the ginseng extract, and the comparison sample 4 In the creatine sample, it was 1.25 times, and it was confirmed that the ginseng (samples 1 and 2) has a myoblast differentiation promoting action.

Example 4
In this example, the muscle atrophy prevention effect of the muscle atrophy inhibitor according to the present invention was evaluated.
Samples for evaluation shown in the following (Table 1) at a rate of 1% to standard diet AIN-93G (manufactured by Japan SLC) to rats (Wistar strain, rabbit, 8 weeks old, 10 animals per group) , 2A, 2B, 5, and 6 were added at 15 g daily for 3 weeks.

  The ginseng ginseng includes the ginseng extract powder (sample 1), ginseng powder (sample 1A), ginseng extract powder (sample 5), and ginseng extract from Matsuura Pharmaceutical Co., Ltd. Ethanol washed products (Samples 2, 2A, 2B) were used. In addition, creatine citrate manufactured by Degussa Bioactives (sample 2A) is used as creatine, C12 peptide (sample 2B) manufactured by DMV is used as casein degrading peptide, and Kikkoman's stock is used as fruit polyphenol. A company-made gravinol super (comparative sample 6) was used. On the other hand, the control group was fed with a standard bait mixed with 1% corn starch (manufactured by Japan SLC).

  From the first week of the test to the final day of the test (the 14th day from the start of the test), the right hind leg of the rat was casted to induce muscle atrophy. On the last day of the test, the right hind limb was dissected and the wet weight of the soleus was measured. The percentage of muscle atrophy was determined by the mean relative value of the right hind leg soleus wet weight when the left hind leg soleus wet weight of the control group was taken as 100. The measurement results are listed below (Table 1).

  As is clear from Table 1, the evaluation samples 1, 2, 2A, 2B, and 5 of the present invention have a higher muscle atrophy prevention effect than the control group and the comparative sample 6. Among the evaluation samples 1, 2, 2A, 2B, and 5 of the present invention, the tannin ginseng water extract ethanol-cleaned product (sample 2) is highly effective in preventing muscle atrophy, and the ninnin ginseng water extract ethanol washes. It was confirmed that the sample 2B using C12 peptide in combination with the product and the sample 2A using creatine together provide a higher muscle atrophy prevention effect.

  The use form of the muscle atrophy inhibitor of the present invention is preferably used as an oral preparation or an external preparation for skin. Below, the combination example (2 examples) which used the muscular atrophy inhibitor of this invention as an oral preparation, and the combination example (2 examples) used as a skin external preparation are illustrated.

(Formulation example 1: oral solution (oral))
Nana ginseng water extract ethanol washed product: 1000 mg, “αG Hesperidin” manufactured by Ezaki Glico Co., Ltd .: 1000 mg, vitamin B ₁ nitrate: 10 mg, ascorbic acid: 500 mg, maltitol: 15000 mg, vitamin B ₆ : 10 mg, inositol: 50 mg, anhydrous caffeine: 20 mg, malic acid: 150 mg, citric acid: 700 mg, sodium citrate: appropriate amount, glycerin: 60 mg, sodium benzoate: 70 mg, and fragrance: a small amount as an internal liquid component, and these are mixed with purified water And dissolved to obtain 100 ml of an internal solution (pH = 4.5).

(Formulation Example 2: Tablet (oral))
Nana ginseng water extract ethanol washed product: 20 g, gelatin: 130 g, glycerin: 70 g, water: 100 g, and ethyl paraoxybenzoate: 0.5 g are heated and stirred to obtain a uniform gelatin dispersion (L1). Obtained.
On the other hand, 100 g of enzyme-decomposed lecithin and 0.4 g of dipotassium glycyrrhizinate were dispersed in 200 g of wheat germ oil using a homomixer to obtain a uniform wheat germ oil solution (L2).
The gelatin dispersion (L1) was extruded into a 12 mm diameter aluminum capsule mold to obtain gelatin capsules.
Next, the wheat germ oil liquid (L2) was extruded through a nozzle and poured into the gelatin capsule, filled, cooled and dried. Thereby, a solid preparation (tablet oral preparation: gel composition) having a gelatinous outer layer of gelatin filled with liquid wheat germ oil liquid (L2) was obtained.

The composition and composition amount per one above-mentioned solid preparation are shown below.
Gelatin: 130 mg (outer layer)
Glycerin: 70mg (outer layer)
Ethyl paraoxybenzoate: 0.5 mg (outer layer)
αG Hesperidin PS: 20 mg (muscle atrophy inhibitor)
Enzymatically decomposed lecithin: 50 mg: (flavoring and flavoring ingredients)
Dipotassium glycyrrhizinate: 0.5 mg (flavoring and flavoring ingredients)
Wheat germ oil 100mg: (inner layer)
Or more, total: 371 mg

(Formulation example 3: patch (external preparation for skin))
The oil layer component and the water layer component shown below were prepared.
The following blending amounts (numbers) represent mass (%) unless otherwise specified.
(Water layer component)
Nana ginseng water extract ethanol washed product: 5.0 g, cetostearyl alcohol: 4.0 g, glyceryl monostearate: 2.0 g, POE (20) sorbitan monolaurate: 2.0 g, glycolic acid: 0 0.2 g, salicylic acid: 0.1 g, pharmacopoeia sulfur: 5.0 g, diglycerin: 5.0 g, resorcinol-labonite complex: 1.0 g, sodium hydroxide: appropriate amount.
(Oil layer component)
Squalane: 10.0 g, liquid paraffin: 3.0 g, beeswax: 2.0 g.
Fragrance: Trace amount, purified water: Balance.

  The oil layer component and the aqueous layer component were separately heated at 70 ° C., then mixed and emulsified. While cooling this, a fragrance was added on the way, and further cooled to room temperature to obtain 100 g of a patch (external skin solvent).

(Formulation 4: Patch sheet (external preparation for skin))
Polyethylene glycol 400 (mass average molecular weight 400): 10.00 g, Tanachi ginseng water extract ethanol-cleaned product: 3.75 g, L-menthol: 2.00 g mixed and dissolved, mixed solution (L3): 15.75 g Obtained.
Next, the rubber-based pressure-sensitive adhesive SIS (trade name “Clayton D-1107”, manufactured by Kraton Polymer Japan Co., Ltd.) heated to 150 ° C .: 73.7 g, and alicyclic hydrocarbon (trade name “Arcon P-100”) “Arakawa Chemical Co., Ltd.)” was mixed at a ratio of 110.55 g to obtain 184.25 g of an adhesive component (M).
Next, the mixed solution (L3): 15.75 g and the adhesive component (M): 184.25 g were added and mixed to obtain a plaster composition: 200 g.
Next, the plaster composition was coated on polyethylene terephthalate (PET, liner) by a hot melt method so that the coating amount (paste mass) was 100 g / m ² after drying. A plaster was obtained.
Finally, the plaster surface of the plaster is coated with a polyurethane film / polyester knit laminated support (knit weight: 30 g / m ² , thickness: 180 μm, moisture permeability: 2200 g, transparency: 49), and a patch A sheet was obtained.

  As described above, the muscle atrophy inhibitor according to the present invention has both the effects of proliferation and differentiation of myoblasts, and based on such effects, effective is a carrot ginseng that exhibits an excellent muscle atrophy suppression effect. Contains as a component. Therefore, by appropriately taking the muscle atrophy inhibitor according to the present invention, it effectively suppresses muscle atrophy that occurs in the case of lack of exercise for a long time due to morbidity or injury, and the quality of life is improved by muscle atrophy. It becomes possible to reduce or prevent damage.

Claims (8)

  A muscular atrophy inhibitor comprising arginaceae ginseng as an active ingredient.   The muscular atrophy inhibitor according to claim 1, comprising the ginseng ginseng in the form of a water extract.   The muscular atrophy inhibitor according to claim 2, wherein the water extract of the ginseng ginseng is purified by washing a crude extract of ginseng ginseng with water with an organic solvent.   The muscle atrophy inhibitor according to claim 3, wherein the organic solvent is 80 to 100% ethanol. The muscular atrophy inhibitor according to any one of claims 1 to 4, wherein the sagittarius ginseng is a ginseng.   Furthermore, the muscular atrophy inhibitor of any one of Claims 1-5 containing 1 type, or 2 or more types chosen from a creatine and a casein degradation peptide.   The muscle atrophy inhibitor according to claim 6, wherein the casein-degrading peptide in the case of containing the casein-decomposing peptide is a C12 peptide.   The muscular atrophy inhibitor according to any one of claims 1 to 7, wherein the muscular atrophy inhibitor is used orally or externally for the skin.